Imatinib Mesylate in Combination With Docetaxel for the Treatment of Patients With Advanced, Platinum-resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis : A Hoosier Oncology Group Trial. Commentary

Saved in:
Bibliographic Details
Published inCancer Vol. 113; no. 4
Main Authors COLEMAN, Robert L, KOHN, Elise C, STEPHENS, Doyle, WHALEN, Charles, SUTTON, Gregory, MATEI, Daniela, EMERSON, Robert E, SCHILDER, Jeanne, MENNING, Nancy, BALDRIDGE, Lee Ann, JOHNSON, Cynthia S, BREEN, Tim, MCCLEAN, John
Format Journal Article
LanguageEnglish
Published New York, NY Wiley-Liss 2008
Subjects
Biological and medical sciences
Female genital diseases
Gynecology. Andrology. Obstetrics
Medical sciences
Tumors
Antineoplastic agent
Phosphorylation
Ovary cancer
platelet-derived growth factor receptors
Cell microenvironment
Cancerology
Platinum
Taxane derivatives
Peritoneal carcinomatosis
Clinical trial
Advanced stage
Antimitotic
kit Gene
Protein-tyrosine kinase
Protooncogene
Primary cancer
Human
docetoxel
phosphorylated kinase B
Drug combination
Imatinib
Platelet derived growth factor receptor
Enzyme
Tyrosine kinase inhibitor
c-kit
ovarian cancer
Transferases
Docetaxel
Enzyme inhibitor
Malignant tumor
Female genital diseases
Resistance
Ovarian diseases
Treatment
Kinase
Abdominal disease
C-Onc gene
Peritoneal cancer
tumor microenvironment
Cancer
Online AccessGet full text

Cover

More Information
ISSN:0008-543X
1097-0142